Investors

News Releases

Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responses Generated promising progression-free survival Demonstrated clinical reversal of platinum resistance and refractoriness Phase 3
May 25, 2023
WESTLAKE VILLAGE, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation  (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately
May 15, 2023
- V-VET1, a clinical-stage animal health-specific product candidate, is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis) - Terms of the agreement grant ELIAS the worldwide right to development and commercialization of V-VET1 for the diagnosis,
November 18, 2021
Displaying 11 - 20 of 25